<p>Inhibikase Therapeutics, Inc.（纽约证券交易所代码：IKT - 免费报告）- Lifesci Capital 在 12 月 1 日（星期一）发布的报告中发布了 Inhibikase Therapeutics 的 2025 财年每股收益（EPS）预估。Lifesci Capital 分析师 C. Jubinville 预计该公司将在本年度发布每股收益（$0.57）。Inhibikase Therapeutics 当前全年的共识预估为每股收益（$0.97）。Lifesci Capital 还发布了 Inhibikase Therapeutics 2025 年第四季度每股收益预估为（$0.12），2026 财年每股收益预估为（$1.00），2027 财年每股收益预估为（$1.00），2028 财年每股收益预估为（$1.10）以及 2029 财年每股收益预估为（$1.00）。</p>
<h2>Inhibikase Therapeutics 股价下跌 6.0%</h2>
<p>Inhibikase Therapeutics 的股票在星期三开盘价为$1.41。该公司的市值为 1.06 亿美元，市盈率为-0.53，贝塔值为 0.89。Inhibikase Therapeutics 的 1 年最低价为$1.33，1 年最高价为$4.20。该公司的 50 日移动平均价为$1.57，200 日移动平均价为$1.71。</p>
<h2>Inhibikase Therapeutics 的机构交易</h2>
<p>几家大型投资者最近增加或减少了对 IKT 的持股。Geode Capital Management LLC 在第二季度将其在 Inhibikase Therapeutics 的持股增加了 228.5%。Geode Capital Management LLC 目前拥有 1,066,700 股该公司的股票，价值$2,080,000，在此期间又购买了 741,940 股。ADAR1 Capital Management LLC 在第三季度将其在 Inhibikase Therapeutics 的持股增加了 2.5%。ADAR1 Capital Management LLC 目前拥有 5,247,603 股该公司的股票，价值$8,501,000，在上个季度又购买了 125,498 股。高盛集团在第一季度将其在 Inhibikase Therapeutics 的持股增加了 277.7%。高盛集团目前拥有 166,025 股该公司的股票，价值$364,000，在此期间又购买了 122,073 股。Jane Street Group LLC 在第一季度购买了 Inhibikase Therapeutics 的新股份，价值约为$255,000。最后，Citadel Advisors LLC 在第三季度购买了 Inhibikase Therapeutics 的新股份，价值约为$116,000。机构投资者持有该公司 3.81% 的股票。</p>
<h2>关于 Inhibikase Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Inhibikase Therapeutics, Inc.是一家临床阶段的制药公司，开发用于帕金森病及相关疾病的治疗药物。其主要产品候选药物是 IkT-148009，一种非受体 Abelson 酪氨酸激酶抑制剂，目前正在进行帕金森病和胃肠道治疗的 2a 期临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Inhibikase Therapeutics</li>
<li>如何投资生物科技股票</li>
<li>Palantir 股票找到立足点——并走向全球增长</li>
<li>股票拆分意味着什么？</li>
<li>1 亿美元的信号：跟随聪明资金进入 DoorDash</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>华尔街的沉睡巨人：亚马逊即将觉醒吗？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Inhibikase Therapeutics 吗？</h2>
<p>在你考虑 Inhibikase Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Inhibikase Therapeutics 并不在名单上。</p>
<p>虽然 Inhibikase Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Lifesci Capital 发布了 Inhibikase Therapeutics 2025 财年的每股收益（EPS）预测，预计每股收益为（$0.57）。当前全年的共识预期为每股（$0.97）亏损。Lifesci 还提供了未来几年的预测，2026 财年预计每股（$1.00）亏损，2029 财年预计每股（$1.00）亏损。Inhibikase 股票下跌 6.0%，市值为 1.06 亿美元。机构投资者已调整在该公司的持股。Inhibikase 开发用于帕金森病的治疗药物，其主要产品正在进行 2a 期临床试验</p>

<p>Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Lifesci Capital issued their FY2025 EPS estimates for Inhibikase Therapeutics in a report issued on Monday, December 1st. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics' current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics' Q4 2025 earnings at ($0.12) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.00) EPS.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics, Inc.（纽约证券交易所代码：IKT - 免费报告）- Lifesci Capital 在 12 月 1 日（星期一）发布的报告中发布了 Inhibikase Therapeutics 的 2025 财年每股收益（EPS）预估。Lifesci Capital 分析师 C. Jubinville 预计该公司将在本年度发布每股收益（$0.57）。Inhibikase Therapeutics 当前全年的共识预估为每股收益（$0.97）。Lifesci Capital 还发布了 Inhibikase Therapeutics 2025 年第四季度每股收益预估为（$0.12），2026 财年每股收益预估为（$1.00），2027 财年每股收益预估为（$1.00），2028 财年每股收益预估为（$1.10）以及 2029 财年每股收益预估为（$1.00）。</p>
</div><h2>Inhibikase Therapeutics Trading Down 6.0%</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 股价下跌 6.0%</h2>
</div><p>Inhibikase Therapeutics stock opened at $1.41 on Wednesday. The firm has a market cap of $106.00 million, a P/E ratio of -0.53 and a beta of 0.89. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $4.20. The firm has a 50-day moving average of $1.57 and a 200-day moving average of $1.71.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics 的股票在星期三开盘价为$1.41。该公司的市值为 1.06 亿美元，市盈率为-0.53，贝塔值为 0.89。Inhibikase Therapeutics 的 1 年最低价为$1.33，1 年最高价为$4.20。该公司的 50 日移动平均价为$1.57，200 日移动平均价为$1.71。</p>
</div><h2>Institutional Trading of Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 的机构交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in IKT. Geode Capital Management LLC lifted its position in shares of Inhibikase Therapeutics by 228.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,066,700 shares of the company's stock worth $2,080,000 after purchasing an additional 741,940 shares during the period. ADAR1 Capital Management LLC raised its stake in Inhibikase Therapeutics by 2.5% in the third quarter. ADAR1 Capital Management LLC now owns 5,247,603 shares of the company's stock worth $8,501,000 after buying an additional 125,498 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Inhibikase Therapeutics by 277.7% in the first quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company's stock worth $364,000 after buying an additional 122,073 shares during the period. Jane Street Group LLC bought a new stake in Inhibikase Therapeutics during the 1st quarter valued at approximately $255,000. Finally, Citadel Advisors LLC bought a new stake in Inhibikase Therapeutics during the 3rd quarter valued at approximately $116,000. Institutional investors own 3.81% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 IKT 的持股。Geode Capital Management LLC 在第二季度将其在 Inhibikase Therapeutics 的持股增加了 228.5%。Geode Capital Management LLC 目前拥有 1,066,700 股该公司的股票，价值$2,080,000，在此期间又购买了 741,940 股。ADAR1 Capital Management LLC 在第三季度将其在 Inhibikase Therapeutics 的持股增加了 2.5%。ADAR1 Capital Management LLC 目前拥有 5,247,603 股该公司的股票，价值$8,501,000，在上个季度又购买了 125,498 股。高盛集团在第一季度将其在 Inhibikase Therapeutics 的持股增加了 277.7%。高盛集团目前拥有 166,025 股该公司的股票，价值$364,000，在此期间又购买了 122,073 股。Jane Street Group LLC 在第一季度购买了 Inhibikase Therapeutics 的新股份，价值约为$255,000。最后，Citadel Advisors LLC 在第三季度购买了 Inhibikase Therapeutics 的新股份，价值约为$116,000。机构投资者持有该公司 3.81% 的股票。</p>
</div><h2>About Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>关于 Inhibikase Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.</p>
<div class="lb-trans"><p>Inhibikase Therapeutics, Inc.是一家临床阶段的制药公司，开发用于帕金森病及相关疾病的治疗药物。其主要产品候选药物是 IkT-148009，一种非受体 Abelson 酪氨酸激酶抑制剂，目前正在进行帕金森病和胃肠道治疗的 2a 期临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Inhibikase Therapeutics</li>
<li>How to Invest in Biotech Stocks</li>
<li>Palantir Stock Finds Its Footing—and a Path to Global Growth</li>
<li>What Does a Stock Split Mean?</li>
<li>The $100 Million Tell: Following Smart Money Into DoorDash</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Inhibikase Therapeutics</li>
<li>如何投资生物科技股票</li>
<li>Palantir 股票找到立足点——并走向全球增长</li>
<li>股票拆分意味着什么？</li>
<li>1 亿美元的信号：跟随聪明资金进入 DoorDash</li>
<li>银行股票 - 最值得投资的银行股票</li>
<li>华尔街的沉睡巨人：亚马逊即将觉醒吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inhibikase Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Inhibikase Therapeutics 吗？</h2>
</div><p>Before you consider Inhibikase Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Inhibikase Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Inhibikase Therapeutics 并不在名单上。</p>
</div><p>While Inhibikase Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Inhibikase Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Lifesci Capital 发布了对 Inhibikase Therapeutics（IKT）2025 财年收益的预估